Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC lifted its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 99.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 140,600 shares of the company’s stock after buying an additional 70,200 shares during the period. Renaissance Technologies LLC owned approximately 0.10% of Compass Therapeutics worth $141,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Ground Swell Capital LLC purchased a new position in Compass Therapeutics during the second quarter worth about $124,000. Rhumbline Advisers boosted its position in shares of Compass Therapeutics by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock worth $132,000 after purchasing an additional 12,315 shares during the period. Panagora Asset Management Inc. acquired a new stake in Compass Therapeutics in the 2nd quarter valued at approximately $68,000. Bank of New York Mellon Corp raised its position in Compass Therapeutics by 12.4% in the second quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock valued at $284,000 after purchasing an additional 31,433 shares during the period. Finally, Opaleye Management Inc. acquired a new position in Compass Therapeutics during the first quarter worth $6,277,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Stock Up 14.5 %

CMPX opened at $1.98 on Monday. Compass Therapeutics, Inc. has a 52 week low of $0.77 and a 52 week high of $2.34. The business’s 50 day moving average is $1.49 and its two-hundred day moving average is $1.39. The firm has a market cap of $272.43 million, a price-to-earnings ratio of -5.50 and a beta of 0.90.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). The company had revenue of $0.85 million for the quarter. Equities analysts expect that Compass Therapeutics, Inc. will post -0.42 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on CMPX. Wedbush reaffirmed an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a research report on Wednesday, August 7th. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a research note on Monday, September 16th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research note on Monday, August 12th.

Compass Therapeutics Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.